Skip to content

Study · Observational study · 2021

3 results

Switching From Daily DPP-4 Inhibitor to Once-Weekly GLP-1 Receptor Activator Dulaglutide Significantly Ameliorates Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes Mellitus: A Retrospective Observational Study.

Sanada J, Kimura T, Shimoda M, Tomita A, Fushimi Y, Kinoshita T, Obata A, Okauchi S, Hirukawa H, Kohara K, Tatsumi F, Nakanishi S, Mune T, Kaku K, Kaneto H

Frontiers in endocrinology6 Aug 2021Cited by 4 (Europe PMC)

PMID34484124 (opens in a new tab)PMCIDPMC8415741 (opens in a new tab)DOI10.3389/fendo.2021.714447 (opens in a new tab)PepBankPUB-34484124
Download PDFPubMedAsk about this study
Jump to 3 results

Summary

AimAt present, daily DPP-4 inhibitors are quite frequently prescribed in subjects with type 2 diabetes mellitus (T2DM). Recently, it has been drawing much attention that once-weekly incretin-based injection dulaglutide was developed. In this study, we aimed to examine the possible effects of once-weekly GLP-1 receptor activator (GLP-1RA) dulaglutide on glycemic control as well as various metabolic parameters.MethodsWe made a direct comparison between the effect of daily DPP-4 inhibitor and once-weekly dulaglutide on glycemic control in "study 1 (pre-post comparison)" and set the control group using the propensity score matching method in "study 2".ResultsIn study 1, switching from daily DPP-4 inhibitor to dulaglutide significantly ameliorated glycemic control in subjects with T2DM. Such effects were more obvious in poorly controlled subjects. After 1:1 propensity score matching, the switching group improved glycemic control compared with the non-switching group in study 2.ConclusionWe should bear in mind that switching from daily DPP-4 inhibitor to once-weekly GLP-1RA dulaglutide exerts more favorable effects on glycemic control regardless of age, body weight, and duration of diabetes in subjects with T2DM, especially when we fail to obtain good glycemic control with daily DPP-4 inhibitor.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study3

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In patients with type 2 diabetes, switching to dulaglutide was linked to improved glycemic control versus prior DPP-4 inhibitor treatment.

    In plain wordsSwitching to dulaglutide was linked to better blood sugar control than prior DPP-4 inhibitor treatment in patients with diabetes.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Direction not reportedGlycemic control after switching
    Study

    n: not reported in source

    Comparator
    Prior daily DPP-4 inhibitor
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In study 1, switching from daily DPP-4 inhibitor to dulaglutide significantly ameliorated glycemic control in subjects with T2DM.
    1 context sentence
    Summary · context
    We made a direct comparison between the effect of daily DPP-4 inhibitor and once-weekly dulaglutide on glycemic control in "study 1 (pre-post comparison)" and set the control group using the propensity score matching method in "study 2".
  2. 02HumanObservational studyEfficacy outcome

    In matched patients with type 2 diabetes, switching to dulaglutide was linked to improved glycemic control versus not switching.

    In plain wordsSwitching to dulaglutide was linked to better blood sugar control than not switching in matched patients with diabetes.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Direction not reportedMatched glycemic control
    Study

    n: not reported in source

    Comparator
    Non-switching group
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    After 1:1 propensity score matching, the switching group improved glycemic control compared with the non-switching group in study 2.
    1 context sentence
    Summary · context
    We made a direct comparison between the effect of daily DPP-4 inhibitor and once-weekly dulaglutide on glycemic control in "study 1 (pre-post comparison)" and set the control group using the propensity score matching method in "study 2".

Studies that did not test the peptide alone1

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

  1. 03HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome

    In patients with type 2 diabetes, glycemic improvement after switching to dulaglutide was more pronounced with poor baseline control.

    In plain wordsAfter switching to dulaglutide, poorer initial blood sugar control was linked to greater improvement in patients with diabetes.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Direction not reportedResponse by baseline control
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    In study 1, switching from daily DPP-4 inhibitor to dulaglutide significantly ameliorated glycemic control in subjects with T2DM. Such effects were more obvious in poorly controlled subjects.
    1 context sentence
    Summary · context
    We made a direct comparison between the effect of daily DPP-4 inhibitor and once-weekly dulaglutide on glycemic control in "study 1 (pre-post comparison)" and set the control group using the propensity score matching method in "study 2".

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.